MA30335B1 - Compositions antibiotiques a liberation modifiee et leur procede de production - Google Patents
Compositions antibiotiques a liberation modifiee et leur procede de productionInfo
- Publication number
- MA30335B1 MA30335B1 MA31291A MA31291A MA30335B1 MA 30335 B1 MA30335 B1 MA 30335B1 MA 31291 A MA31291 A MA 31291A MA 31291 A MA31291 A MA 31291A MA 30335 B1 MA30335 B1 MA 30335B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibiotic
- dosage form
- release
- hours
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques à libération modifiée innovantes qui comprennent au moins un antibiotique, de préférence de l'amoxicilline ou ses sels, esters, polymorphes, isomères, promédicaments, solvates, hydrates ou dérivés pharmaceutiquement acceptables, seul ou en combinaison avec un ou des autres antibiotiques en tant que matière active, avec au moins un agent modificateur de la libération destiné à réguler la libération du bêta lactame antibiotique, facultativement avec un ou plusieurs autres excipients pharmaceutiquement acceptables, la forme pharmaceutique assurant une libération ne dépassant pas environ 60 % de l'antibiotique en environ 30 minutes et n'étant pas inférieure à environ 70 % de l'antibiotique après 8 heures dans une étude de dissolution in vitro ou lors d'un essai in vivo. L'invention concerne en outre des compositions qui, lors d'essais sur un groupe d'humains en bonne santé, fournit une concentration plasmatique maximale moyenne (Cmax) au moins environ 0,5 heure après l'administration de la forme pharmaceutique. La présente invention concerne également des procédés de préparation d'une telle forme pharmaceutique et des procédés d'utilisation d'une telle forme pharmaceutique.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN824DE2006 | 2006-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30335B1 true MA30335B1 (fr) | 2009-04-01 |
Family
ID=38540834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31291A MA30335B1 (fr) | 2006-03-24 | 2008-10-15 | Compositions antibiotiques a liberation modifiee et leur procede de production |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090111788A1 (fr) |
EP (1) | EP2001465A1 (fr) |
JP (1) | JP2009530367A (fr) |
KR (1) | KR20090006123A (fr) |
CN (1) | CN101410109A (fr) |
AU (1) | AU2007230546A1 (fr) |
BR (1) | BRPI0709179A2 (fr) |
CA (1) | CA2644911A1 (fr) |
CR (1) | CR10388A (fr) |
EA (1) | EA200870368A1 (fr) |
MA (1) | MA30335B1 (fr) |
MX (1) | MX2008012260A (fr) |
RS (1) | RS20080430A (fr) |
TN (1) | TNSN08348A1 (fr) |
WO (1) | WO2007110875A1 (fr) |
ZA (1) | ZA200807943B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010004556A (es) * | 2007-10-26 | 2010-07-01 | Rexahn Pharmaceuticals Inc | Formulacion farmaceutica de acido clavulanico. |
US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
WO2010038691A1 (fr) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | Composition pharmaceutique particulaire destinée à être administrée oralement |
KR20120012823A (ko) * | 2009-04-29 | 2012-02-10 | 렉산 파마슈티컬스, 인코포레이티드 | 신경보호 및 퇴행성 신경 질환 치료용 클라블라네이트 제제 |
US20130131033A1 (en) * | 2010-01-13 | 2013-05-23 | Toyochem Laboratories | Pharmaceutical composition for treatment of respiratory tract infections |
WO2011152808A1 (fr) * | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique |
CN102861015B (zh) * | 2011-07-05 | 2015-07-08 | 北京乐维生物技术有限公司 | 一种稳定的阿莫西林克拉维酸钾缓释制剂及其制备工艺 |
US20150238425A1 (en) * | 2012-08-28 | 2015-08-27 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Mini-tablets |
US9254261B2 (en) * | 2014-03-03 | 2016-02-09 | Sandoz Ag | Stable quick dissolving dosage form comprising amoxicillin and clavulanic acid |
WO2015153984A2 (fr) | 2014-04-04 | 2015-10-08 | Pharmaquest International Center, LLC | Comprimés monolithiques à libération modifiée se désintégrant, contenant des granules à libération prolongée quadri-couches |
US10335374B2 (en) * | 2014-12-04 | 2019-07-02 | University System of Georgia, Valdosta State University | Tablet composition for anti-tuberculosis antibiotics |
JP2018507209A (ja) * | 2015-02-20 | 2018-03-15 | サイテック インダストリーズ インコーポレイテッド | ジアルキルスルホスクシナート組成物、製造方法、および使用方法 |
JP7370125B2 (ja) * | 2018-11-09 | 2023-10-27 | 日本化薬株式会社 | エルロチニブを有効成分とする医薬錠剤 |
JP7370124B2 (ja) * | 2018-11-09 | 2023-10-27 | 日本化薬株式会社 | エルロチニブを有効成分とする医薬錠剤 |
CN113116860B (zh) * | 2021-04-22 | 2022-11-25 | 海南通用三洋药业有限公司 | 一种阿莫西林胶囊及其制备方法 |
CN113398069A (zh) * | 2021-07-10 | 2021-09-17 | 四川成康动物药业有限公司 | 兽用阿莫西林与磺胺嘧啶钠混悬注射液及制备方法和装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9201930D0 (sv) * | 1992-06-24 | 1992-06-24 | Astra Ab | Gastric antibacterial treatment |
EP1330236A2 (fr) * | 2000-10-12 | 2003-07-30 | Beecham Pharmaceuticals (Pte) Limited | Nouvelle formulation |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
-
2007
- 2007-03-07 KR KR1020087026154A patent/KR20090006123A/ko not_active Application Discontinuation
- 2007-03-07 US US12/294,353 patent/US20090111788A1/en not_active Abandoned
- 2007-03-07 JP JP2009501021A patent/JP2009530367A/ja not_active Abandoned
- 2007-03-07 CN CNA2007800105961A patent/CN101410109A/zh active Pending
- 2007-03-07 EA EA200870368A patent/EA200870368A1/ru unknown
- 2007-03-07 RS RSP-2008/0430A patent/RS20080430A/sr unknown
- 2007-03-07 MX MX2008012260A patent/MX2008012260A/es not_active Application Discontinuation
- 2007-03-07 AU AU2007230546A patent/AU2007230546A1/en not_active Abandoned
- 2007-03-07 BR BRPI0709179-6A patent/BRPI0709179A2/pt not_active IP Right Cessation
- 2007-03-07 CA CA002644911A patent/CA2644911A1/fr not_active Abandoned
- 2007-03-07 ZA ZA200807943A patent/ZA200807943B/xx unknown
- 2007-03-07 EP EP07736547A patent/EP2001465A1/fr not_active Withdrawn
- 2007-03-07 WO PCT/IN2007/000086 patent/WO2007110875A1/fr active Search and Examination
-
2008
- 2008-09-09 TN TNP2008000348A patent/TNSN08348A1/en unknown
- 2008-10-15 MA MA31291A patent/MA30335B1/fr unknown
- 2008-10-21 CR CR10388A patent/CR10388A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RS20080430A (en) | 2009-05-06 |
US20090111788A1 (en) | 2009-04-30 |
MX2008012260A (es) | 2008-10-07 |
TNSN08348A1 (en) | 2009-12-29 |
AU2007230546A1 (en) | 2007-10-04 |
EA200870368A1 (ru) | 2009-04-28 |
CA2644911A1 (fr) | 2007-10-04 |
CR10388A (es) | 2009-01-19 |
JP2009530367A (ja) | 2009-08-27 |
BRPI0709179A2 (pt) | 2011-06-28 |
EP2001465A1 (fr) | 2008-12-17 |
CN101410109A (zh) | 2009-04-15 |
WO2007110875A1 (fr) | 2007-10-04 |
ZA200807943B (en) | 2009-11-25 |
KR20090006123A (ko) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30335B1 (fr) | Compositions antibiotiques a liberation modifiee et leur procede de production | |
Rajeswari et al. | Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson’s disease induced by MPTP neurodegeneration in mice | |
EP3288553B1 (fr) | Combinaisons de cannabinoïdes et de n-acyléthanolamines | |
JP6720301B2 (ja) | 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をin vivoで増強する方法 | |
Xue et al. | Melatonin mediates protective effects against kainic acid-induced neuronal death through safeguarding ER stress and mitochondrial disturbance | |
US20210393645A1 (en) | Treatment for progressive multiple sclerosis | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
JP2010505958A (ja) | 神経防護作用組成物および方法 | |
CA2611201A1 (fr) | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques | |
MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
Krzysztoforska et al. | Administration of protocatechuic acid affects memory and restores hippocampal and cortical serotonin turnover in rat model of oral D-galactose-induced memory impairment | |
US11311539B2 (en) | Compositions and methods for treatment of fragile X syndrome | |
WO2013003729A1 (fr) | Compositions, méthodes et nécessaires pour traiter la leucémie | |
Kiyofuji et al. | A natural compound macelignan protects midbrain dopaminergic neurons from inflammatory degeneration via microglial arginase-1 expression | |
US20070167446A1 (en) | Neuroprotective compounds and pharmaceutical compositions comprising them | |
He et al. | Inhibition of HSP90β by ganetespib blocks the microglial signalling of evoked pro-inflammatory responses to heat shock | |
US20170304251A1 (en) | Avocado-derived lipids for use in treating leukemia | |
WO2020145331A1 (fr) | Médicament pour la prévention ou le traitement de maladies neurodégératives | |
DZ3273A1 (fr) | Nouvelle forme galenique orale a liberation prolongee de la molsidomine | |
WO2008075321A3 (fr) | Formulations à libération modifiée de dérivés azabicyclo |